Pentanoic acid, 5-[[(1,1-dimethylethoxy)carbonyl]methylamino]- | 124073-08-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Pentanoic acid, 5-[[(1,1-dimethylethoxy)carbonyl]methylamino]-
• 英文别名: 5-[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]pentanoic acid
• CAS: 124073-08-1
• 化学式: C₁₁H₂₁NO₄
• 分子量: 231.29
• InChiKey: ASAGFKSDTZKBRT-UHFFFAOYSA-N

物化性质

• 沸点：
  345.1±21.0 °C(Predicted)
• 密度：
  1.073±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR<br/>[FR] CONCEPTION ET SYNTHESE DE LIGANDS OPTIMISE POUR PPAR
  申请人：BETHESDA PHARMACEUTICALS INC

  公开号：WO2005009437A1

  公开（公告）日：2005-02-03

  This invention provides new chemical entities useful for treating a variety of clinical disorders including those that areinfluenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5­adamantan-2-yl-pentanoic acid 2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.

  这项发明提供了新的化学实体，可用于治疗各种临床疾病，包括那些受过氧化物酶体增殖物激活受体（PPAR）活性影响的疾病。提供了这些化合物的结构以及设计、制造和使用这些化合物的方法。提供了在牛皮癣病例中使用这些化合物的治疗组合物的化合物和方法。提供了一个具有以下结构的示例化合物：5-金刚烷基-2-基戊酸2-[4-(2,4-二氧-噻唑啉-5-基-甲基)-苯氧基]-乙基}-甲基酰胺。
• Water-Soluble Prodrugs of Florfenicol and its Analogs
  申请人：Glinka Tomasz W.

  公开号：US20080188556A1

  公开（公告）日：2008-08-07

  The present invention discloses certain novel prodrugs of florfenicol and/or of florfenicol analogs, including prodrugs of salts pharmaceutically acceptable salts of florfenicol and its analogs, including nitrogen-containing esters of the secondary alcohol group of florfenicol and of its analogs, and pharmaceutically acceptable salts thereof, compositions containing them, and methods of administering them to subjects. In particular embodiments the prodrugs are sufficiently water-soluble to serve the functions needed of a water-soluble prodrug of florfenicol or of a water-soluble prodrug of a florfenicol analog. A certain subclass of the compounds also possesses the hydrolytic stability needed to maintain the prodrug in solution in the subject's system until appropriate conditions exist when the prodrug can hydrolyze, releasing florfenicol or the florfenicol analog in question.

  本发明揭示了某些新型氟苯菲酚和/或氟苯菲酚类似物的前药，包括氟苯菲酚及其类似物的可接受药用盐的前药，包括氟苯菲酚和其类似物的次级醇基的含氮酯前药及其药用可接受盐，含有它们的组合物以及将它们用于给予受试者的方法。在特定实施例中，这些前药具有足够的水溶性，以发挥氟苯菲酚或氟苯菲酚类似物的水溶性前药所需的功能。某些化合物的亚类也具有水解稳定性，以保持前药在受试者的系统中溶解，直到存在适当的条件使前药水解，释放所需的氟苯菲酚或氟苯菲酚类似物。
• Modulators of Chemokine Receptor Activity
  申请人：Weigand Klaus

  公开号：US20080306067A1

  公开（公告）日：2008-12-11

  A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.

  公式为（I）的化合物，其取代基如上所述，在治疗由CCR3作用介导的疾病中有用，特别是炎症或阻塞性气道疾病。
• DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
  申请人：Bethesda Pharmaceuticals, Inc.

  公开号：EP1646383A1

  公开（公告）日：2006-04-19
• EP1646383A4
  申请人：——

  公开号：EP1646383A4

  公开（公告）日：2009-03-25